COVID-19 Evidence Reviews
as of 12/1/20
menu
 
 

Candidate Therapeutics
 
= living review
= draft/preprint   |  
= meets mimimum quality standards   |  

A review with this mark was peer-reviewed, described systematic search and study selection, and included critical appraisal of primary studies.
latest update
date
report
select
11/27/20
Dar-Odeh N, Elsayed S, Babkair H, et al. | J Dent Sci
Aim: To highlight COVID-19 pharmacotherapeutic agents that are relevant to dental practice in terms of their clinical indications in COVID-19 and dental practice, as well as their adverse effects as they impact the dental patient.
CANDIDATE THERAPEUTICS
11/24/20
Perveen RA, Nasir M, Talha KA, et al. | Med J Malaysia
Aim: To evaluate the effectiveness of antiviral therapies in the treatment of COVID-19.
CANDIDATE THERAPEUTICS
11/20/20
Takla M, Jeevaratnam K | Saudi Pharm J
Aim: To systematically identify and collate 24 studies describing the use of CQ and HCQ in human clinical trials and to provide a detailed synthesis of evidence of its efficacy and safety.
CANDIDATE THERAPEUTICS
11/20/20
Nunes JPL | Porto Biomed J
Aim: To perform a systematic review on mortality associated to the use of ACEi in patients with COVID-19 disease.
CANDIDATE THERAPEUTICS
11/20/20
Faraone I, Labanca F, Ponticelli M, et al. | Molecules
Aim: To analyze preclinical and clinical studies on HCQ potential use in viral infection and chronic diseases.
CANDIDATE THERAPEUTICS
11/20/20
Zreiq R, Haouas N, Khemakhem AM, et al. | J of Pharmaceutical Res
Aim: To review the "state-of-the-art" of treatment modalities and propose a practical therapeutic algorithm for the COVID-19 management.
CANDIDATE THERAPEUTICS
11/20/20
Zhao M, Lu J, Tang Y, et al. | Eur J Clin Pharmacol
Aim: To explore the effectiveness and safety of tocilizumab recently used for treating COVID-19.
CANDIDATE THERAPEUTICS
11/19/20
Lim ZJ, Subramaniam A, Reddy MP, et al. | Am J Respir Crit Care Med
Aim: To examine the case fatality rate of patients with COVID-19 receiving invasive medical ventilation.
CANDIDATE THERAPEUTICS
11/18/20
Kaye A, Siegel R | PeerJ
Aim: To investigate and synthesize existing evidence for the efficacy of TCZ in reducing COVID-19 mortality.
RECENTLY UPDATED
CANDIDATE THERAPEUTICS
11/16/20
Joseph B, Dibas M, Evanson KW, et al. | Expert Rev Anti Infect Ther
Aim: To systematically review the clinical literature reporting the use of Lopinavir/ritonavir (LPV/r) for the treatment of patients with COVID-19 to assess the efficacy of LPV/r for the treatment of Cornonavirus disease 19 (COVID-19).
CANDIDATE THERAPEUTICS
11/11/20
Tleyjeh IM, Kashour Z, Damlaj M, et al. | Clin Microbiol Infect
Aim: To perform a living systematic review of the literature about the efficacy and toxicity of the IL-6 receptor antagonist, tocilizumab, in COVID-19 patients.
CANDIDATE THERAPEUTICS
11/11/20
Oscanoa TJ, Vidal X, Kanters JK, et al. | Int J Antimicrob Agents
Aim: To conduct a meta-analysis of the frequency of LQT in patients with SARS-CoV-2 infection treated with HCQ.
CANDIDATE THERAPEUTICS
11/11/20
Tleyjeh I, Kashour Z, Al Dosary O, et al. | Mayo Clin Proc Innov Qual Outcomes
Aim: To systematically review the literature and estimate the risk of cardiac toxicity in patients receiving CQ or HCQ for COVID-19.
UPDATED
CANDIDATE THERAPEUTICS
11/9/20
Ren L, Xu W, Overton JL, et al. | Front Pharmacol
Aim: To examine the safety profiles of these medications, we systematically evaluated the adverse events (AEs) of these medications from published randomized controlled trials (RCTs).
UPDATED
CANDIDATE THERAPEUTICS
10/28/20
Mora-Ramirez M, Melgoza-Hernandez P, Toledo-Ramirez SE, et al. | Curr Med Chem
Aim: To review the main adverse effects regarding the most prescribed drugs and, specifically, the efficacy and potential risk of each pharmacological therapy, during hospital care for COVID-19.
CANDIDATE THERAPEUTICS
10/27/20
Budhathoki P, Shrestha DB, Rawal E, et al. | SN Compr Clin Med
Aim: To assess the rationality on the use of corticosteroids in COVID-19.
UPDATED
CANDIDATE THERAPEUTICS
10/26/20
Weatherald J, Solverson K, Zuege DJ, et al. | J Crit Care
Aim: To quickly identify and synthesize studies examining the effect of awake prone positioning on patients with hypoxemic respiratory failure (including those with ARDS and/or COVID-19).
UPDATED
CANDIDATE THERAPEUTICS
10/26/20
Mch SA, Baishya M, Singh A, et al. | Trends Anaesthesia Crit Care
Aim: To conduct a systematic review of the available literature to highlight the effect of awake proning on the need for intubation, improvement in oxygenation and mortality rates in COVID-19 patients with ARDS.
CANDIDATE THERAPEUTICS
10/26/20
Hu C, Liang M, Gong F, et al. | Evid Based Complement Alternat Med
Aim: To investigate and compare the therapeutic effect of Lianhua Qingwen with conventional drugs on pneumonia symptoms.
CANDIDATE THERAPEUTICS
10/26/20
Wang Y, Chen B, Li Y, et al. | J Med Virol
Aim: To investigate the effects of ACEI/ARB on COVID-19 patients.
CANDIDATE THERAPEUTICS
10/25/20
Kotak S, Khatri M, Malik M, et al. | Cureus
Aim: To assess the safety and efficacy of tocilizumab as compared to the standard regimen in patients with COVID-19.
CANDIDATE THERAPEUTICS
10/22/20
Wijaya I, Andhika R, Huang I | Clin Appl Thromb Hemost
Aim: To explore the association between therapeutic-dose anticoagulation and its effect on mortality in patients with COVID-19.
CANDIDATE THERAPEUTICS
10/22/20
Kurdi A, Abutheraa N, Akil L, et al. | Pharmacol Res Perspect
Aim: To provide a comprehensive/updated evaluation of the effect of ACEIs/ARBs on COVID?19?related clinical outcomes, including exploration of interclass differences between ACEIs and ARBs.
CANDIDATE THERAPEUTICS
10/22/20
Qadri SK, Ng P, Toh TSW, et al. | Pulm Ther
Aim: To describe the mechanisms of action of prone position, systematically appraise the current experience of prone position in COVID-19 patients, and highlight unique considerations for prone position practices during this pandemic.
CANDIDATE THERAPEUTICS
10/22/20
Ayele Mega T, Feyissa TM, Dessalegn Bosho D, et al. | Can Respir J
Aim: To generate an up-to-date evidence for the clinical safety and efficacy of hydroxychloroquine (HCQ) with or without azithromycin (AZ) among patients treated for COVID-19.
CANDIDATE THERAPEUTICS
10/21/20
Agstam S, Yadav A, Kumar MP, et al. | Indian Pacing Electrophysiol J
Aim: To study the risk of QTc prolongation and Torsades de pointes (TdP) by a well-defined criterion for HCQ, CQ alone, and in combination with Azithromycin in patients with COVID-19.
CANDIDATE THERAPEUTICS
10/21/20
Bhattacharyya A, Kumar S, Sarma P, et al. | Indian J Pharmacol
Aim: To evaluate the safety as well as efficacy of L/R combination therapy in the management of COVID-19.
CANDIDATE THERAPEUTICS
10/20/20
Kotecha P, Light A, Checcucci E, et al. | Panminerva Med
Aim: To evaluate the data currently available regarding the repurposing of different drugs for Covid-19 treatment. 
UPDATED
CANDIDATE THERAPEUTICS
10/20/20
Sun C, Sun Y, Li X | Am J Emerg Med
Aim: To evaluate the clinical efficacy and safety of CM in the treatment of COVID-19 pneumonia.
CANDIDATE THERAPEUTICS
10/19/20
Fram G, Wang D, Malette K, et al. | Curr Cardiol Rev
Aim: To evaluate the incidence of cardiotoxicity associated with hydroxychloroquine prior to onset of the COVID-19 pandemic.
CANDIDATE THERAPEUTICS
10/19/20
Cantini F, Goletti D, Petrone L, et al. | Drugs
Aim: To assess the clinical impact of different therapies for COVID-19.
CANDIDATE THERAPEUTICS
10/13/20
Chai KL, Valk SJ, Piechotta V, et al. | Cochrane Database Syst Rev
Aim: To assess whether convalescent plasma or hyperimmune immunoglobulin transfusion is effective and safe in the treatment of people with COVID?19.
UPDATED
CANDIDATE THERAPEUTICS
10/13/20
Kashour ZT, Riaz M, Garbati M, et al. | J Antimicrob Chemother
Aim: To systematically evaluate the effect of CQ and HCQ with or without azithromycin (AZ) on outcomes of COVID-19 patients.
UPDATED
CANDIDATE THERAPEUTICS
10/13/20
Prodromos C, Rumschlag T | New Microbes New Infect
Aim: To review the efficacy of HCQ against COVID-19.
CANDIDATE THERAPEUTICS
10/10/20
Yokoyama Y, Aikawa T, Takagi H, et al. | J Med Virol
Aim: To investigate the effect of ACEI and ARB on mortality and susceptibility to COVID-19.
CANDIDATE THERAPEUTICS
10/9/20
Li Y, Li J, Zhang Y, et al. | Chin J Integr Med
Aim: To systematically review the clinical practice guidelines for the treatment of coronavirus disease 2019 (COVID-19) patients with Chinese herbal medicine (CHM), summarize their recommendations and evaluate their qualities.
CANDIDATE THERAPEUTICS
10/6/20
Cheng W, Li Y, Cui L, et al. | Front Pharmacol
Aim: To evaluate the efficacy and safety of corticosteroid therapy in patients with COVID-19.
UPDATED
CANDIDATE THERAPEUTICS
10/5/20
Tlayjeh H, Mhish O, Enani M, et al. | J Infect Public Health
Aim: To systematically review the literature about the association between systemic corticosteroid therapy (CST) and outcomes of COVID-19 patients.
UPDATED
CANDIDATE THERAPEUTICS
10/5/20
Wilt TJ, Kaka AS, MacDonald R, et al. | Ann Intern Med
Aim: To evaluate the effectiveness and harms of remdesivir for COVID-19.
CANDIDATE THERAPEUTICS
10/2/20
Flumignan RLG, de Sa Tinoco JD, Pascoal PIF, et al. | Cochrane Database Syst Rev
Aim: To assess the effects of prophylactic anticoagulants versus active comparator, placebo or no intervention, on mortality and the need for respiratory support in people hospitalised with COVID?19.
UPDATED
CANDIDATE THERAPEUTICS
9/28/20
Shrestha DB, Pudhathoki P, Khadka S, et al. | Virol J
Aim: To review the efficacy and safety of favipiravir triphosphate as a treatment for COVID-19.
UPDATED
CANDIDATE THERAPEUTICS
9/24/20
Malgie J, Schoones JW, Pijls BG | Clin Infect Dis
Aim: To review the evidence on the use of IL-6 (receptor) antagonist therapy in reducing mortality in COVID-19 patients.
CANDIDATE THERAPEUTICS
9/24/20
Wang M, Wu T, Zuo Z, et al. | BMJ Support Palliat Care
Aim: To summarize the efficacy and safety of antiviral agents currently in use for COVID-19 treatment.
UPDATED
CANDIDATE THERAPEUTICS
9/21/20
Yang T, Chou C, Yang Y, et al. | J Chin Med Assoc
Aim: To address not only the benefits and safety issues of HCQ in COVID-19 treatment and to evaluate the effects in combination with the use of macrolide, especially AZI in therapy.
CANDIDATE THERAPEUTICS
9/21/20
Khalaj K, Figueira RL, Antounians L, et al. | J Extracell Vesicles
Aim: To analyse whether EV-based therapies could be effective in treating severe pulmonary conditions that affect COVID-19 patients and to understand their relevance for an eventual therapeutic application to human patients. 
CANDIDATE THERAPEUTICS
9/18/20
WHO REACT Working Group | JAMA
Aim: To estimate the association between administration of corticosteroids compared with usual care or placebo and 28-day all-cause mortality.
WHO COLLABORATIVE
CANDIDATE THERAPEUTICS
9/18/20
Paknahad Z, Moravejolahkami AR | Endocr Metab Immune Disord Drug Targets
Aim: To review the evidence on the effects of probiotics on incidence, severity, duration, and other clinical manifestations of viral infections especially SARS-CoV-2-induced.
CANDIDATE THERAPEUTICS
9/18/20
Campbell CM, Guha A, Haque T, et al. | J Clin Med
Aim: To characterize the current state of immunotherapy trials in COVID-19, and focuses on associated cardiotoxicities, given the importance of pharmacovigilance.
CANDIDATE THERAPEUTICS
9/17/20
Dambha-Miller H, Albasri A, Hodgson S, et al. | BMJ Open
Aim: To review evidence on routinely prescribed drugs in the UK that could upregulate or downregulate ACE2 and potentially affect COVID-19 disease.
UPDATED
CANDIDATE THERAPEUTICS
9/17/20
Juul S, Nielsen N, Feinberg J, et al. | PLoS Med
Aim: To compare the effects of all treatment interventions for participants in all age groups with COVID-19. 
UPDATED
CANDIDATE THERAPEUTICS
9/15/20
Yamamoto V, Bolanos JF, Fiallos J, et al. | J Alzheimers Dis
Aim: To provide a comprehensive review of SARS-CoV-2-induced disease, its mechanism of infection, diagnostics, therapeutics, and treatment strategies, while also focusing on less attended aspects by previous studies, including nutritional support, psychological, and rehabilitation of the pandemic and its management.
CANDIDATE THERAPEUTICS
9/14/20
Siemieniuk RAC, Bartoszko JJ, Ge L, et al. | BMJ
Aim: To compare the effects of treatments for coronavirus disease 2019 (covid-19).
UPDATED
CANDIDATE THERAPEUTICS
9/14/20
Aziz M, Haghbin H, Sitta EA, et al. | J Med Virol
Aim: To compare the efficacy of addition of TOC to standard of care (SOC) versus SOC in patients with COVID?19.
CANDIDATE THERAPEUTICS
9/14/20
Hasan SS, Kow CS, Hadi MA, et al. | Am J Cardiovasc Drugs
Aim: To critically examine the association of RAS inhibitors use with mortality and disease severity in COVID-19.
CANDIDATE THERAPEUTICS
9/14/20
Cozzupoli GM, Savastano MC, Galsini B, et al. | J Ophthalmol
Aim: To review and analyze previous studies conducted on ritonavir administration and retinal impairment in a narrative synthesis. 
CANDIDATE THERAPEUTICS
9/14/20
Zeng M, Li L, Wu Z | PLoS ONE
Aim: To review the evidence on the clinical efficacy and safety of the traditional Chinese medicine Lianhua Qingwen in the treatment of new coronavirus pneumonia (COVID-19). 
CANDIDATE THERAPEUTICS
9/12/20
Hussain N, Yoganathan A, Hewage S, et al. | Expert Rev Anti Infect Ther
Aim: To identify studies pertaining to antivirals, both as sole and combined therapies, in COVID-19 patients and review the clinical outcomes of these treatment methods.
CANDIDATE THERAPEUTICS
9/11/20
Usman AS, Siddiqi TJ, Khan MS, et al. | Am J Cardiol
Aim: To conduct a meta-analysis of all available data on the relationship between renin-angiotensin aldosterone system of inhibitors and COVID-19.
CANDIDATE THERAPEUTICS
9/11/20
Sun M, Xu Y, He H, et al. | Int J Infect Dis
Aim: To explore the effectiveness of treatment and predict the potential effects of CP with COVID-19.
CANDIDATE THERAPEUTICS
9/11/20
Bakhtawar N, Usman M, Khan MMU | Cureus
Aim: To evaluate the efficacy of convalescent plasma (CP) therapy and its effects on COVID-19 patient outcomes.
CANDIDATE THERAPEUTICS
9/11/20
Pathak SK, Salunke AA, Thivari P, et al. | Diabets Metab Syndr
Aim: To evaluate the efficacy of hydroxychloroquine and its related formulations in COVID-19 patients.
CANDIDATE THERAPEUTICS
9/10/20
Chastain DB, Stitt TM, Ly PR, et al. | Open Forum Infect Dis
Aim: To assess potential proinflammatory targets and review the safety and efficacy of immunomodulatory therapies in managing patients with acute respiratory distress syndrome associated with coronavirus disease 2019.
CANDIDATE THERAPEUTICS
9/9/20
Razmi M, Hashemi F, Gheytanchi E, et al. | Int Immunopharmacol
Aim: To assess the available data regarding the efficacy of the immunomodulatory drugs used to manage COVID-19.
UPDATED
CANDIDATE THERAPEUTICS
9/9/20
Kow CS, Hasan SS | J Med Virol
Aim: To explore whether the use of metformin was associated with decreased mortality in COVID-19 patients.
CANDIDATE THERAPEUTICS
9/9/20
Seyedpour S, Khodaei B, Loghman AH, et al. | J Cell Physiol
Aim: To provide a systematic evaluation of the most recent in vitro and in vivo investigations targeting SARS?CoV?2 cell entry.
CANDIDATE THERAPEUTICS
9/8/20
Elavarasi A, Prasad M, Seth T, et al. | J Gen Intern Med
Aim: To synthesize the available data on the efficacy and safety of CQ and HCQ for the treatment of COVID-19.
UPDATED
CANDIDATE THERAPEUTICS
9/8/20
Zang Y, Han X, He M, et al. | Naunyn Schmiedebergs Arch Pharmacol
Aim: To systematically assess the benefits and harms of HCQ for the treatment of COVID-19.
CANDIDATE THERAPEUTICS
9/8/20
Vargas M, Servillo G, Einav S | Eur Rev Med Pharmacol Sci
Aim: To review the evidence on the use of lopinavir/ritonavir for the treatment of SARS, MERS, and SARS-CoV-2.
CANDIDATE THERAPEUTICS
9/4/20
Sarkar S, Khanna P, Soni KD | J Med Virol
Aim: To evaluate the impact of glucocorticoid therapy in COVID-19 patients based on the publications reported to date.
CANDIDATE THERAPEUTICS
9/3/20
de Andrade KRC, da Silva Carvalho VK, Farinasso CM, et al. | Cien Saude Colet
Aim: To evaluate the effects of drug therapies for coronavirus infections. 
CANDIDATE THERAPEUTICS
9/3/20
Bendezu-Quispe G, Rodirquez-Zuniga MJM, Roman YM, et al. | Rev Peru Med Exp Salud Publica
Aim: To review the evidence on chloroquine/hydroxychloroquine, lopinavir/ritonavir, tocilizumab, oseltamivir, interferon, atazanavir and anti SARS-CoV-2 serum as therapeutic agents for COVID-19.
CANDIDATE THERAPEUTICS
9/2/20
Cumpstey AF, Oldman AH, Smith AF, et al. | Cochrane Database of Systematic Reviews
Aim: To address how oxygen therapy should be targeted in adults with ARDS (particularly ARDS secondary to COVID?19 or other respiratory viruses) and requiring mechanical ventilation in an intensive care unit, and the impact oxygen therapy has on mortality, days ventilated, days of catecholamine use, requirement for renal replacement therapy, and quality of life.
CANDIDATE THERAPEUTICS
9/2/20
Chan CK, Huang YS, Liao HW, et al  | Hypertension
Aim: To review the evidence on the impact of the use of ACEi or ARBs on SARS-CoV-2 infection.
CANDIDATE THERAPEUTICS
9/1/20
Liu M, Ya G, Yuan Y, et al. | Integr Med Res
Aim: To evaluate the efficacy and safety of LH for treating patients with COVID-19 by a systematic review and meta-analysis.
CANDIDATE THERAPEUTICS
9/1/20
Baroutjian A, Sanchez C, Boneva D, et al. | Am J Emerg Med
Aim: To evaluate the safety and effectiveness of SARS-CoV-2 pharmacologic therapies as of August 2, 2020 according to study level of evidence.
CANDIDATE THERAPEUTICS
8/31/20
Bakhtawar N, Usman M, Khan MHU | Cureus
Aim: To provide an insight into the clinical effectiveness of convalescent plasma as a potential therapy for COVID-19 patients.
CANDIDATE THERAPEUTICS
8/31/20
Fiolet T, Guihur A, Rebeaud M, et al. | Clin Microbiol Infect
Aim: To assess whether chloroquine or hydroxychloroquine with or without azithromycin decreased COVID-19 mortality compared to the standard of care.
UPDATED
CANDIDATE THERAPEUTICS
8/31/20
Das RR, Jaiswal N, Dev N, et al. | Front Med
Aim: To review the evidence on the efficacy and safety of using anti-malarial drugs to treat COVID-19.
CANDIDATE THERAPEUTICS
8/31/20
Ullah W, Abdullah HM, Roomi S, et al. | J Clin Med Res
Aim: To review the evidence on the use of hydroxycholorquine to treat COVID-19.
CANDIDATE THERAPEUTICS
8/31/20
Nasir M, Perveen RA, Saha SK, et al. | Mymensingh Med J
Aim: To evaluate the role of favipiravir along with its safety and efficacy for the patients who are suffering from severe acute respiratory distress syndrome due to CoronaVirus-2 (SARS-CoV-2) as re-purposeful use.
CANDIDATE THERAPEUTICS
8/27/20
Prodromos CC | New Microbes New Infect
Aim: To review the evidence on cardiac arrhythmic mortality caused by the use of hydroxychloroquine and azithromycin.
CANDIDATE THERAPEUTICS
8/26/20
Pang W, Liu Z, Li Y, et al. | Integr Med Res
Aim: To evaluate the efficacy and safety of CMD for COVID-19.
CANDIDATE THERAPEUTICS
8/26/20
Arentz S, Yang G, Goldenberg J, et al. | Adv Integr Med
Aim: To assess the effects of zinc on the incidence, duration and severity of acute upper or lower respiratory tract infections caused by SARS-CoV-2 infection in people of any age and of any zinc status when used as a preventive supplement or as a therapy.
CANDIDATE THERAPEUTICS
8/26/20
Schloss J, Lauche R, Harnett J, et al. | Adv Integr Med
Aim: To review the evidence on the effect of Vitamin C on acute respiratory tract infections in adults when administered at the onset of symptoms.
CANDIDATE THERAPEUTICS
8/26/20
Frediansyah A, Nainu F, Dhama K, et al. | Clin Epidemiol Glob Health
Aim: To summarize the antiviral activities of remdesivir against SARS-CoV-2, the causative agent of COVID-19.
CANDIDATE THERAPEUTICS
8/26/20
Hariyanto TI, Kurniawan A | Diabetes Metab Syndr
Aim: To analyze the association between statin use and in-hospital outcomes of COVID-19 infection.
CANDIDATE THERAPEUTICS
8/26/20
Siordia JA, Bernaba M, Yoshino K, et al. | SN Compr Clin Med
Aim: To compile the current data regarding human controlled COVID-19 treatment trials.
CANDIDATE THERAPEUTICS
8/26/20
Leeson CE, Ismail A, Hashad MM, et al. | SN Compr Clin Med
Aim: To review and summarize what is known about COVID-19 and the current implications of intravesical BCG with regard to the disease.
CANDIDATE THERAPEUTICS
8/26/20
Aucoin M, Cooley K, Saunders PR, et al. | Adv Integr Med
Aim: To review the role of quercetin in the treatment and recovery of COVID-19 and other respiratory tract infections.
CANDIDATE THERAPEUTICS
8/26/20
Aucoin M, Cooley K, Saunders PR, et al. | Adv Integr Med
Aim: To review the role of Echinacea in the prevention and treatment of COVID-19 and other respiratory tract infections.
CANDIDATE THERAPEUTICS
8/25/20
Baral R, White M, Vassiliou VS | Curr Atheroscler Rep
Aim: To review the evidence on the impact RAAS inhibitor use has in antihypertensive COVID-19 hospitalised patients.
UPDATED
CANDIDATE THERAPEUTICS
8/23/20
Jovic TH, Ali SR, Ibrahim N, et al. | Nutrients
Aim: To investigate whether vitamin supplementation is beneficial in COVID-19.
UPDATED
CANDIDATE THERAPEUTICS
8/21/20
Karlsen APH, Wiberg S, Laigaard J, et al. | PLoS One
Aim: To provide a global snapshot overview of interventions and main methodological aspects of planned and initiated randomised clinical trials on COVID-19 prevention and treatment. 
CANDIDATE THERAPEUTICS
8/21/20
Talaie H, Hosseini SM, Nazari M, et al. | Daru
Aim: To synthesize the results of well-done observational studies and clinical trials to estimate the value of some clinical managements to confront COVID-19.
CANDIDATE THERAPEUTICS
8/21/20
Abdel-Maboud M, Menshawy A, Elgebaly A, et al. | J Thromb Thrombolysis
Aim: To investigate whether prophylactic heparin use is associated with reduction in thromboembolic events. 
CANDIDATE THERAPEUTICS
8/20/20
Misra S, Nath M, Hadda V, et al. | Eur J Clin Invest
Aim: To assess the efficacy of various treatment modalities in nCOV-2019 patients.
CANDIDATE THERAPEUTICS
8/19/20
Elsawah H, Elsokary MA, Elrazzaz M, et al. | J Med Virol
Aim: To assess the evidence strength of hydroxychloroquine efficacy in treating COVID-19 arising from clinical trials and to update the practice with the most reliable clinical evidence.
CANDIDATE THERAPEUTICS
8/19/20
Luo X, Ni X, Lin J, et al. | Phytomedicine
Aim: To investigate the efficacy and safety of CHM or CHM combination therapy for COVID-19.
CANDIDATE THERAPEUTICS
8/15/20
Fan AF, Gu S, Alemi AF, et al. | J Integr Med
Aim: To summarize contemporary studies that report the use of Chinese herbal medicine (CHM) to treat COVID-19.
CANDIDATE THERAPEUTICS
8/15/20
Rakedzon S, Khoury Y, Rozenberg G, et al. | Rambam Maimonides Med J
Aim: To review the existing clinical evidence of HCQ use for the prevention and treatment of COVID-19.
CANDIDATE THERAPEUTICS
8/12/20
Kow CS, Hasan SS | Am J Cardiol
Aim: To summarise the existing evidence on the effect of statins on the clinical outcomes of COVID-19 from adjusted analyses.
CANDIDATE THERAPEUTICS
8/11/20
Sarkar S, Soni KD, Khanna P | J Med Virol
Aim: To evaluate the impact of CPT in COVID-19 patients based on the publications reported to date.
CANDIDATE THERAPEUTICS
8/9/20
Xu X, Shi Y, Wang R, et al. | Integr Med Res
Aim: To comprehensively summarize and analyze the current guidelines on home-based traditional Chinese medicine (TCM) nursing interventions for discharged patients with COVID-19.
CANDIDATE THERAPEUTICS
8/9/20
Barochiner J, Martinez R | J Clin Pharm Ther
Aim: To compare the occurrence of severe and fatal COVID-19 in infected patients who were under treatment with angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) vs no treatment or other antihypertensives.
UPDATED
CANDIDATE THERAPEUTICS
8/9/20
Baladia E, Pizarro AB, Ortiz-Munoz L, et al. | Medwave
Aim: To provide a timely, rigorous, and continuously updated summary of the available evidence on the role of vitamin C in treating patients with COVID-19.
UPDATED
CANDIDATE THERAPEUTICS
8/7/20
Liu X, Long C, Ziong Q, et al. | Clin Cardiol
Aim: To review the current evidence and assess the clinical prognosis of COVID?19 patients with or without hypertension treated with ACEs/ARBs.
CANDIDATE THERAPEUTICS
8/7/20
Chi G, Lee JJ, Jamil A, et al. | J Clin Med
Aim: To offer benchmark data on the incidence of VTE and to examine the difference in D-dimer levels among anticoagulated COVID-19 patients with and without VTE incident. 
UPDATED
CANDIDATE THERAPEUTICS
8/3/20
Putman M, Chock YPE, Tam H, et al. | Arthritis Rheumatol
Aim: To identify and summarize research that describes the use of antirheumatic disease therapies for the treatment of COVID-19.
CANDIDATE THERAPEUTICS
8/2/20
Volpe M, Battistoni A | Int J Cardiol
Aim: To review the evidence on the potential role of renin-angiotensin system inhibitors, specifically angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, with regard to COVID-19 disease and mortality.
CANDIDATE THERAPEUTICS
8/1/20
Hasan SS, Capstick T, Ahmed R, et al. | Expert Rev Respair Med
Aim: To review ARDS-associated mortality and the potential role of systemic corticosteroids in COVID-19 patients.
CANDIDATE THERAPEUTICS
7/30/20
Musa A, Pendi K, Hashemi A, et al. | West J Emerg Med
Aim: To review the evidence on the use of remdesivir for the treatment of COVID-19.
CANDIDATE THERAPEUTICS
7/28/20
Jin X, Chua HZ, Wang K, et al. | Integr Med Res
Aim: To summarize all the clinical studies to generate reliable evidence for decision-making on the medicinal value of Squama Manitis.
CANDIDATE THERAPEUTICS
7/28/20
Cortegiani A, Ippolito M, Greco M, et al. | Pulmonology
Aim: To describe the rationale for the use of tocilizumab for the treatment of COVID-19 and to summarize the available evidence regarding its efficacy. and safety.
CANDIDATE THERAPEUTICS
7/28/20
Haiduc AA, Alom S, Melamed N, Harky A | J Card Surg
Aim:  To examine the literature evidence behind using extracorporeal membrane oxygenation in COVID?19 patients in a systematic review manner.
CANDIDATE THERAPEUTICS
7/28/20
Lan S, Lai C, Huang H, et al. | Int J Antimicrob Agents
Aim: To assess the efficacy of tocilizumab for the treatment of severe coronavirus disease-2019 (COVID-19).
CANDIDATE THERAPEUTICS
7/25/20
Solis-Garcia Del Pozo J, Galindo MF, Nava E, et al. | Eur Rev Med Pharmacol Sci
Aim: To review the evidence on the role of IL-6 in treating COVID-19.
CANDIDATE THERAPEUTICS
7/24/20
Venkatesulu BP, Chandrasekar VT, Giridhar P, et al. | J Med Virol
Aim: To do a systematic review and critical appraisal of the ongoing clinical trials that are assessing various therapeutic interventions against SARS-CoV-2 with an aim to provide insight into the various interventions tested, clinical rationale, geographical distribution of the trials as well as the endpoints assessed in the studies.
UPDATED
CANDIDATE THERAPEUTICS
7/21/20
Vidali S, Morosetti D, Cossu E, et al. | ERJ Open Res
Aim: To highlight the correlation between elevated D-dimer (an indirect thrombosis marker) and the increased rate of poor prognosis-associated conditions, and to introduce D-dimer-labelled anticoagulant administration as a potentially useful tool to prevent complications and positively influence coronavirus disease 2019 (COVID-19) course.
CANDIDATE THERAPEUTICS
7/20/20
Cortegiani A, Ingoglia G, Ippolito M, et al. | J Crit Care
Aim: To evaluate the efficacy and safety of chloroquine and chloroquine-related formulations in patients with SARS-CoV-2 pneumonia and articles describing related in-vitro studies.
UPDATED
CANDIDATE THERAPEUTICS
7/17/20
Greco A, Buccheri S, D'Arrigo P, et al. | Eur Heart J Cardiovasc Pharmacother
Aim: To review the evidence on the impact of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on the clinical outcomes of COVID-19 patients.
UPDATED
CANDIDATE THERAPEUTICS
7/15/20
Chandrasekar VT, Venkatesalu B, Patel HK, et al. | J Med Virol
Aim: To assess if any intervention provides mortality benefit, other clinically relevant outcomes and also ascertain the safety profile.
UPDATED
CANDIDATE THERAPEUTICS
7/10/20
Yu C, Kang L, Chen J, et al. | Int Immunopharmacol
Aim: To recapitulate relevant studies to evaluate the safety, efficacy, tolerability and treatment-related outcomes of type I IFNs for coronavirus infection in clinical practice, with expectation to provide more robust evidence whether IFNs should be served as first-line agents for coronavirus infection, including the SARS-CoV-2.
CANDIDATE THERAPEUTICS
7/8/20
Sun M, Xu Y, He H, et al. | Int J Infect Dis
Aim: To explore the effectiveness of treatment and predict the potential effect of convalescent plasma for COVID-19.
CANDIDATE THERAPEUTICS
7/8/20
Zhu R, Gao Y, Robert S, et al. | J Transl Med
Aim: To summarize the characteristics of clinical trials for COVID-19.
CANDIDATE THERAPEUTICS
7/6/20
Xiong X, Wang P, Su K, et al. | Pharmacol Res
Aim: To evaluate the current clinical evidence on Chinese herbal medicine for the treatment of COVID-19.
CANDIDATE THERAPEUTICS
7/3/20
Huang D, Yu H, Wang T, et al. | J Med Virol
Aim: To evaluate the efficacy and safety of umifenovir in COVID?19.
CANDIDATE THERAPEUTICS
7/1/20
Alizadeh F, Khodavandi A | IEEE Trans Nanobioscience
Aim: To summarize the available evidence on the efficacy of nanoscale materials against coronaviruses in vitro and in animal models.
CANDIDATE THERAPEUTICS
7/1/20
Munir MA, Kuganda H, Basry A | Sys Rev Pharm
Aim: To review the evidence on the best and safe antivirus medication to cure COVID-19.
CANDIDATE THERAPEUTICS
7/1/20
Flacco ME, Martellucci CA, Bravi F et al. | Heart
Aim: To summarise the existing evidence on the association between these medications and severe/lethal COVID-19.
CANDIDATE THERAPEUTICS
6/23/20
Lu S, Zhou Q, Huang L, et al. | Ann Transl Med
Aim: To review the evidence on the use of glucocorticoids in treating COVID-19.
UPDATED
CANDIDATE THERAPEUTICS
6/23/20
Zhang J, Yang Y, Yang N, et al. | Ann Transl Med
Aim: To explore the clinical effectiveness and safety of IVIG in the treatment of children with severe COVID-19.
UPDATED
CANDIDATE THERAPEUTICS
6/23/20
Wang J, Tang Y, Ma Y, et al. | Ann Transl Med
Aim: To evaluate the efficacy and safety of antibiotic agents in children with COVID-19, as well as to introduce the present situation of antibiotics use and bacterial coinfections in COVID-19 patients. 
UPDATED
CANDIDATE THERAPEUTICS
6/23/20
Shi Q, Zhou Q, Wang X, et al. | Ann Transl Med
Aim: To assess the potential effectiveness and safety of antiviral agents for COVID-19 in children. 
UPDATED
CANDIDATE THERAPEUTICS
6/20/20
Maldonado E, Tao D, Mackey K | J Gen Intern Med
Aim: To synthesize evidence on thromboembolism incidence and outcomes with antithrombotic therapies in COVID-19.
UPDATED
VA ESP
CANDIDATE THERAPEUTICS
6/17/20
Di Lorenzo G, Di Trolio R, Kozlakidis Z, et al. | Crit Rev Oncol Hematol
Aim: To review the evidence on the clinical outcomes of COVID-19-positive patients and the possible interactions between drugs used in experimental therapy of COVID-19 and commonly used antineoplastic drugs.
CANDIDATE THERAPEUTICS
6/14/20
Heidary F, Gharebaghi R | J Antibiot (Tokyo)
Aim: To summarize the antiviral effects of ivermectin by reviewing available in vivo and in vitro studies over the past 50 years.
CANDIDATE THERAPEUTICS
6/13/20
Zhu T, Xu A, Bai X, et al. | Zhonghua Wei Zhong Bing Ji Jiu Yi Xue
Aim: To systematically review evidence for the effect of convalescent plasma and immunoglobulin on treatment of severe acute respiratory syndrome (SARS), and further provide advice on the treatment of coronavirus disease 2019 (COVID-19).
CANDIDATE THERAPEUTICS
6/9/20
Patel TK, Barvaliya M, Kevadiya BD, et al. | J Neuroimmune Pharmacol
Aim: To find out early trends of mortality in COVID-19 patients treated with hydroxychloroquine based on published literature.
CANDIDATE THERAPEUTICS
6/9/20
Nasir M, Talha KA, Islam T, et al. | Mymensingh Med J
Aim:  To evaluate the available evidence on efficacy, safety to identify any promising role for compassionate use of remdesivir in patient suffered for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) as re-purposeful use. 
CANDIDATE THERAPEUTICS
6/8/20
Lima WG, Brito J, Overhage J, et al. | Arch Virol
Aim: To describe the drug repositioning strategy against SARS-CoV-2 and to discuss the clinical impact of this approach in the current pandemic context. 
CANDIDATE THERAPEUTICS
6/5/20
Bhagavathula AS, Aldhaleei WA, Rovetta A, et al. | Cureus
Aim: To extract and summarize information on potential vaccines and therapeutic agents against COVID-19 at different stages of clinical trials from January to March 2020.
CANDIDATE THERAPEUTICS
6/4/20
Ye Z, Wang Y, Colunga-Lozano LE, et al. | CMAJ
Aim: To examine the impact of corticosteroids in COVID-19 and related severe acute respiratory illnesses to support a guideline for managing COVID-19.
CANDIDATE THERAPEUTICS
6/3/20
Liu W, Zhou P, Chen K, et al. | CMAJ
Aim: To support the development of a COVID-19 management guideline by reviewing evidence that addressed the benefits and harms of 7 antiviral treatments for COVID-19.
CANDIDATE THERAPEUTICS
5/28/20
Das S, Bhowmick S, Tiwari S, et al. | Clin Drug Investig
Aim: To systematically review the therapeutic role of HCQ in COVID-19 from the available literature.
CANDIDATE THERAPEUTICS
5/27/20
Hernandez AV, Roman YM, Pasupuleti V, et al. | Ann Intern Med
Aim: To summarize evidence about the benefits and harms of hydroxychloroquine or chloroquine for the treatment or prophylaxis of coronavirus disease 2019 (COVID-19).
CANDIDATE THERAPEUTICS
5/27/20
Fajgenbaum DC, Khor JS, Gorzewski A, et al. | Infect Dis Ther
Aim: To systematically evaluate the treatments adminstered to COVID-19 patients.
UPDATED
CANDIDATE THERAPEUTICS
5/26/20
Rodrigo C, Fernando SD, Rajapakse S | Clin Microbiol Infect
Aim: To summarize evidence from human clinical studies for using HCQ or CQ as antiviral agents for any viral infection.
CANDIDATE THERAPEUTICS
5/23/20
Ang L, Song E, Lee HW, et al. | J Clin Med
Aim: To evaluate the effectiveness and adverse events of herbal medicines for the treatment of COVID-19.
CANDIDATE THERAPEUTICS
5/22/20
Devasenapathy N, Ye Z, Loeb M, et al. | CMAJ
Aim: To review the safety and efficacy of convalescent plasma in severe coronavirus disease 2019 (COVID-19) patients for guideline development
CANDIDATE THERAPEUTICS
5/21/20
Antwi-Amoabeng D, Kanji Z, Ford B, et al. | J Med Virol
Aim: To summarize the baseline characteristics of COVID-19 patients who received tocilizumab in order to identify nuanced predictors of response to therapy and other clinical outcomes.
CANDIDATE THERAPEUTICS
5/20/20
Nemati H, Ramezani M, Najafi F, et al. | Open Access Maced J Med Sci
Aim: To check the association between ACE2 and COVID-19 (coronavirus disease 2019) in a systematic review. 
CANDIDATE THERAPEUTICS
5/19/20
Sachdeva M, Mufti A, Maliyar K, et al. | J Am Acad Dermatol
Aim: To conduct a systematic review of previously reported cases of psoriasis onset, exacerbation, or relapse after HCQ treatment.
CANDIDATE THERAPEUTICS
5/15/20
Zhang X, Yu J, Pan L, et al. | Pharmacol Res
Aim: To (1) determine whether use of ACRI/ARB is associated with an increase in likelihood of viral infectivity; (2) to investigate whether there are differences in severity and mortality between ACRI/ARB users and non- ACRI/ARB users; (3) and, in particular, to evaluate whether ACRI/ARB exposure was associated with a lower risk of mortality when compared to non-ACRI/ARB antihypertensive drug exposure. 
CANDIDATE THERAPEUTICS
5/14/20
Gbinigie K, Frie K | BJGP Open
Aim: To review the evidence for the effectiveness and safety of azithromycin in treating COVID-19.
CANDIDATE THERAPEUTICS
5/12/20
Singh AK, Singh A, Shaikh A, et al. | Diabets Metab Syndr
Aim: To review existing literature and relevant websites regarding these drugs and COVID-19, adverse effects related to drugs, and related guidelines.
CANDIDATE THERAPEUTICS
5/12/20
Rajendran K, Narayanasamy K, Rangarajan J, et al. | J Med Virol
Aim: To evaluate the effectiveness of CPT therapy in COVID-19 patients based on the publications reported till date.
CANDIDATE THERAPEUTICS
5/12/20
Veronese N, Demurtas J, Yang L, et al. | Front Med
Aim: To investigate the effectiveness of glucocorticoid therapy in patients with COVID-19.
CANDIDATE THERAPEUTICS
5/11/20
Patil VM, Singhal S, Masand N | Life Sci
Aim: To review the evidence on the mechanism of action, safety (side effects, adverse effects, toxicity) and details of clinical trials for chloroquine and hydroxychloroquine.
CANDIDATE THERAPEUTICS
5/11/20
Ricco M, Gualerzi G, Ranzieri S et al. | Acta Biomed
Aim: To review the evidence on the role of the BCG vaccine as a preventive and/or therapeutic option against COVID-19.
CANDIDATE THERAPEUTICS
5/10/20
Liu M, Gao Y, Yuan Y, et al. | Pharmacol Res
Aim: To assess the efficacy and safety of Integrated Traditional Chinese and Western Medicine to corona virus disease 2019 (COVID-19). 
CANDIDATE THERAPEUTICS
5/10/20
Jankelson L, Karam G, Becker ML, et al. | Heart Rhythm
Aim: To conduct a systematic review of the arrhythmogenic effect of short courses of chloroquine or hydroxychloroquine.
CANDIDATE THERAPEUTICS
5/8/20
Li Z, Wang X, Cao D, et al. | Drug Discov Ther
Aim: To critically assess the potential anti-coronavirus effect of remdesivir on COVID-19 and other coronaviruses based on the most up-to-date evidence.
CANDIDATE THERAPEUTICS
5/5/20
Li H, Chen C, Hu F, et al. | Leukemia
Aim: To determine safety and efficacy of corticosteroids in SARS-CoV-2, SARS-CoV, and MERS-CoV infections.
CANDIDATE THERAPEUTICS
5/2/20
Chowdhury M, Rathod J, Gernsheimer J | Acad Emerg Med
Aim: To review literature currently available regarding the clinical use of CQ and HCQ as treatment in COVID-19 patients in an effort to catalog their recommendations and assess drug efficacy.
CANDIDATE THERAPEUTICS
4/30/20
Zhong H, Wang Y, Zhang Z, et al. | Pharmacol Res
Aim: To evaluate the efficacy and safety of current option of therapies for severe acute respiratory syndrome (SARS), Middle Eastern respiratory syndrome (MERS) besides COVID-19, in an attempt to identify promising therapy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected patients.
CANDIDATE THERAPEUTICS
4/27/20
Halpin D, Singh D, Hadfield RM | Eur Respir J
Aim: To evaluate whether pre-morbid use or continued administration of inhaled steroids is a risk factor for adverse outcomes in acute respiratory infections due to COVID-19, SARS or MERS. 
WHO COLLABORATIVE
CANDIDATE THERAPEUTICS
4/21/20
Yousefifard M, Zali A, Mohamed A, et al. | Arch Acad Emerg Med
Aim: To evaluate the efficacy of antiviral therapies in treatment of COVID-19.
CANDIDATE THERAPEUTICS
4/21/20
Alzghari SK, Acuna VS | J Clin Virol
Aim: To evaluate outcomes associated with TCZ treatment in patients with COVID-19.
CANDIDATE THERAPEUTICS
4/17/20
Tobaigy M, Qashgary M, Al-Dahery S, et al. | Infect Prev Pract
Aim: To report any evidence of therapeutics used for the management of COVID-19 patients in clinical practice since the emergence of the virus.
CANDIDATE THERAPEUTICS
4/17/20
Sarma P, Kaur H, Kumar H, et al. | J Med Virol
Aim: To examine the evidence for the safety and efficacy of hydroxycholorquine in COVID-19.
CANDIDATE THERAPEUTICS
4/14/20
Shah S, Das S, Jain A, et al. | Int J Rheum Dis
Aim: To systematically review the role of CQ and HCQ in preventing the spread of COVID-19.
CANDIDATE THERAPEUTICS
4/14/20
Yang Z, Liu J, Zhou Y, et al. | J Infect
Aim: To further evaluate the influence of corticosteroids on patients with coronavirus infection.
CANDIDATE THERAPEUTICS
4/10/20
Aminjafari A, Ghasemi S | Int Immunopharmacol
Aim: To evaluate the existing evidence and experience related to immunotherapy for 2019-nCoV.
CANDIDATE THERAPEUTICS
4/9/20
Gbinigie K, Kerstin F | BJGP Open
Aim: To establish the current evidence for the effectiveness of CQ and HCQ in treating COVID-19.
CANDIDATE THERAPEUTICS
4/1/20
Roman BR, Moscoso S, Chung SA, et al. | Revista Cubana de Farmacia
Aim: To review the evidence about the effectiveness and adverse reactions of the drugs currently used against COVID-19 in Peru and Bolivia.
CANDIDATE THERAPEUTICS
3/29/20
Lin A, Hye W, Jun Y, et al.  | Integr Med Res
Aim: To summarize and analyze the herbal formulae provided by the guidelines for their pattern identifications (PIs) and compositions of herbs to treat patients with COVID-19
CANDIDATE THERAPEUTICS
2/25/20
Rios P, Radhakrishnan A, Antony J, et al. | Public Health Agency of Canada
Aim: To identify safe and effective medical countermeasures (e.g., antivirals/antibodies) to address the current outbreak of a novel coronavirus (COVID-19)
CANDIDATE THERAPEUTICS
2/14/20
Zhang L, Liu Y | J Med Virol
Aim: To summarize therapeutic options available for the treatment of COVID-19
CANDIDATE THERAPEUTICS
2/1/20
Prajapat M, Sarma P, Shekhar N, et al. | Indian J Pharmacol
Aim: To describe protein structures that are potential targets for the development of CoV therapies
CANDIDATE THERAPEUTICS